10/524,451 m-1 Yong Chu 9-22-2006

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:38:26 ON 22 SEP 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:38:49 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2
DICTIONARY FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10524451\10524451M-1.str





chain nodes :
1 2 3 4 5 6 16 17
ring nodes :
7 8 9 10 11 12 13 14 15
chain bonds :
1-2 2-3 3-4 4-5 5-6 14-16 15-17

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

close. but not art

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:12973 CAPLUS Full-text
DOCUMENT NUMBER: 132:30325
TITLE: New .alpha.-Substituted Succinate-Based Hydroxamic Acids as TNF.alpha. Convertase Inhibitors
AUTHOR(S): Barlaam, Bernard; Bird, T. Geoffrey; Lambert-van der Brempt, Christine; Campbell, Douglas; Foster, Steve J.; Maciewicz, Rose
CORPORATE SOURCE: Centre de Recherches, AstraZeneca Zeneca Pharma, Reims, 51689, Fr.
SOURCE: Journal of Medicinal Chemistry (1999), 42(23), 4890-4908
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tumor necrosis factor .alpha. convertase (TACE), the enzyme responsible for the processing of pro-TNF.alpha. to TNF.alpha., has been reported to be a metalloproteinase closely related to matrix metalloproteinases (MMPs). Current inhibitors of TACE such as succinate-based hydroxamic acids exemplified by Marimastat (TACE IC50: 3.8 nM; blood IC50: 7 .mu.M) and BB1101 (TACE IC50: 0.2 nM; blood IC50: 2.3 .mu.M) suffer from modest potency in blood and poor in vivo properties. The introduction of new bulky .alpha.-substituents into these succinate-based hydroxamic acids was studied. Substituents such as thioethers, sulfonamides, and ethers showed improved potency against TACE when compared with Marimastat. Although this improvement did not translate into better blood potency for thioether or ether substituents, the sulfonamide series exhibited improved potency both against TACE and in blood when compared with Marimastat. Optimization of this sulfonamide series has culminated in the identification of heterocyclic bicyclic sulfonamides as good TACE inhibitors.

IT 204125-83-7P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(new .alpha.-substituted succinate-based hydroxamic acids as TNF.alpha. convertase inhibitors)

RN 204125-83-7 CAPLUS
CN L-Valinamide, (3R)-N2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-N-hydroxy-3-(2-methylpropyl)-L-.alpha.-asparaginyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 204126-28-3P 204126-29-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(new .alpha.-substituted succinate-based hydroxamic acids as TNF.alpha. convertase inhibitors)
RN 204126-28-3 CAPLUS
CN L-Valinamide, (3R)-N-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-3-(2-methylpropyl)-L-.beta.-aspartyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204126-29-4 CAPLUS
CN L-Valinamide, (3R)-N-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-3-(2-methylpropyl)-L-.beta.-aspartyl-N,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:161082 CAPLUS Full-text
DOCUMENT NUMBER: 128:205148

TITLE: Preparation of peptide sulfonamides as inhibitors of tumor necrosis factor

INVENTOR(S): Barlaam, Bernard Christophe

PATENT ASSIGNEE(S): Zeneca Limited, Fr.

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807742	A1	19980226	WO 1997-GB2222	19970819
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9740217	A1	19980306	AU 1997-40217	19970819
ZA 9707580	A	19990217	ZA 1997-7580	19970822

PRIORITY APPLN. INFO.:

FR 1996-1815	A	19960823
FR 1996-2031	A	19960925
EP 1996-401815	A	19960823
EP 1996-402031	A	19960925
WO 1997-GB2222	W	19970819

OTHER SOURCE(S): MARPAT 128:205148

AB Peptide sulfonamides HONHCOCH(NHSO2R1)CHR2CONHCHR3CONR4R5 (R1 = aryl, heterocyclyl, heteroaryl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, aryl-, heteroaryl-, heterocyclyl- or cycloalkylalkyl; R3 = alkyl, alkenyl, aryl, alkyl, heteroarylalkyl or the side-chain of a naturally occurring amino acid; R4 = H, alkyl, cycloalkyl, cycloalkenyl, aryl-, heteroaryl- or heterocyclylalkyl; R5 = H, alkyl or R4R5N = heterocyclyl; any group or ring in R1-R5 is optionally substituted) or their pharmaceutically acceptable salts or in vivo hydrolyzable esters were prepd. as inhibitors of the prodn. of tumor necrosis factor and/or one or more matrix metalloproteinase enzymes. Thus, N2-[4-(hydroxyamino)-2R-isobutyl-3S-benzenesulfonylaminosuccinyl]-L- leucine-N1-methylamide was prepd. via sequential benzenesulfonylation, deprotection, and hydroxylamination of intermediate N2-[2R-isobutyl-3S- amino-4-tert-butyloxysuccinyl]-L-leucine-N1-methylamide.

IT 204125-83-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide sulfonamides as inhibitors of tumor necrosis factor)

RN 204125-83-7 CAPLUS

CN L-Valinamide, (3R)-N2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-N-hydroxy-3-(2-methylpropyl)-L-.alpha.-asparaginyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 204126-28-3P 204126-29-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptide sulfonamides as inhibitors of tumor necrosis factor)
RN 204126-28-3 CAPLUS
CN L-Valinamide, (3R)-N-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-3-(2-methylpropyl)-L-.beta.-aspartyl-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204126-29-4 CAPLUS
CN L-Valinamide, (3R)-N-[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]-3-(2-methylpropyl)-L-.beta.-aspartyl-N,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.82	189.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 16:41:33 ON 22 SEP 2006

ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-15 13-14 14-15
exact/norm bonds :
1-2 4-5 5-6 11-13 12-15 13-14 14-15 14-16 15-17
exact bonds :
2-3 3-4
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 19:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:39:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 720 TO 1640
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:39:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1558 TO ITERATE

100.0% PROCESSED 1558 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.38 167.59

FILE 'CAPLUS' ENTERED AT 16:39:44 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 21 Sep 2006 (20060921/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1021739 CAPLUS Full-text
DOCUMENT NUMBER: 143:326208
TITLE: Preparation of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors
INVENTOR(S): Eissenstat, Michael; Guerassina, Tatiana
PATENT ASSIGNEE(S): Sequoia Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087728	A1	20050922	WO 2005-US8381	20050311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

US 2005209301 A1 20050922 US 2005-77135 20050311
PRIORITY APPLN. INFO.: US 2004-552643P P 20040311
OTHER SOURCE(S): MARPAT 143:326208
GI



II

AB Title compds. X-A-B-A'-X' [X = 5-7 membered non-arom. heterocycle; A = ZCZNH, ZCOCONH, ZSO2NH, etc.; Z = amino, O, S, etc.; B = syn-CH(D)CH(OH)CH2; D = alk(en/yn)yl; aryl, cycloalkyl, etc.; A' = ND'-E'; D' = alk(en/yn)yl, aryl, cycloalkyl, etc.; E' = CO, SO, SO2; X' = indolyl; I] are prepd. For instance, II is prepd. in several steps from 2-oxo-2,3-dihydro-1H-indol-5-sulfonyl chloride (prepn. given), [1-benzyl-2-hydroxy-4-phenylbutyl]isobutylcarbamic acid benzyl ester, carbonic acid 2,5-dioxopyrrolidin-1-yl ester hexahydrofuro[2,3-b]furan-3- yl ester and DMF di-Me acetal. II has an IC50 = 93 nM for a recombinant wild type HIV protease. I are useful for treating HIV infections.

IT 664344-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diamino-mono-ol dipeptide isostere core based resistance-repellent retroviral protease inhibitors)

RN 664344-17-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN Current appl.
ACCESSION NUMBER: 2004:162694 CAPLUS Full-text
DOCUMENT NUMBER: 140:210820
TITLE: Broad spectrum substituted oxindole sulfonamide HIV protease inhibitors
INVENTOR(S): Tahri, Abdellah; Wigerinck, Piet Tom Bert Paul
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004016619	A1	20040226	WO 2003-EP50379		20030814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2493940	AA	20040226	CA 2003-2493940		20030814
AU 2003262574	A1	20040303	AU 2003-262574		20030814
BR 2003005771	A	20041005	BR 2003-5771		20030814
EP 1546153	A1	20050629	EP 2003-787818		20030814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1688586	A	20051026	CN 2003-824095		20030814
JP 2005537305	T2	20051208	JP 2004-528524		20030814
US 2006058368	A1	20060316	US 2005-524451		20050210
NO 2005001291	A	20050518	NO 2005-1291		20050314
PRIORITY APPLN. INFO.:			EP 2002-78384	A	20020814
			WO 2003-EP50379	W	20030814

OTHER SOURCE(S): MARPAT 140:210820
GI



I



II

AB The present invention concerns the compds. having the formula (I) N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters, and metabolites thereof [wherein R1, R8 = H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, aryl, Het1, Het1-C1-6 alkyl, etc.; or R1 = (un)substituted H2N-CH2CH; t is 0, 1 or 2; R2 = H, C1-6 alkyl; L = CO, O-CO, NR8CO, O-C1-6 alkanediyl-CO, NR8-C1-6alkanediyl-CO, SO2, O-SO2, NR8-SO2; R3 = (un)substituted C1-6 alkyl, aryl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, aryl-C1-4alkyl; R4 = H, C1-4 alkyl-O-CO, carboxyl, CONH2, mono- or di(C1-4alkyl)carbamoyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl; R6 = H, (un)substituted C1-6 alkyl; Het1 is a 5 to 10 ring membered mono- or bicyclic heterocycle contg. .gtoreq.1 heteroatoms selected from N, O, and S]. It further relates to their use as broad spectrum HIV protease inhibitors, pharmaceutical compns., and a method for treating or combating infection or disease assocd. with multi-drug resistant retrovirus infection in a mammal. It also may concern combinations thereof with another anti-retroviral agent, and to their use in assays as ref. compds. or as reagents. These compds. I exhibited potent anti-HIV activity against a wild type lab. HIV strain (HIV-1 strain L-AI), e.g. sec50 of 8.5 for the compd. (II), and also were effective in inhibiting a broad range of mutant strains which show various degrees of phenotypic cross-resistance to the currently com. available drugs such as for instance saquinavir, ritonavir, nelfinavir, indinavir and amprenavir.

IT 664344-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted oxindolesulfonamide derivs. for use as broad spectrum HIV protease inhibitors)

RN 664344-17-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/524,451M Yong Chu 9-22-2006

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUl 14	FSTA enhanced with Japanese patents
NEWS	14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:15:18 ON 22 SEP 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:15:32 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2
DICTIONARY FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10524451\10524451M.str





chain nodes :
1 2 3 4 5 6 16 17 18
ring nodes :
7 8 9 10 11 12 13 14 15
chain bonds :

```
1-2  2-3  3-4  4-5  5-6  13-16  14-17  15-18
ring bonds :
7-8  7-12  8-9  9-10  10-11  11-12  11-13  12-15  13-14  14-15
exact/norm bonds :
1-2  4-5  5-6  11-13  12-15  13-14  14-15  14-17  15-18
exact bonds :
2-3  3-4  13-16
normalized bonds :
7-8  7-12  8-9  9-10  10-11  11-12

G1:H,Ak

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:Atom  8:Atom  9:Atom
10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:CLASS  20:Atom



L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
 G1 H,Ak


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 16:18:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       14 TO ITERATE

100.0% PROCESSED       14 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           56 TO      504
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1
```

```
=> s l1 full
FULL SEARCH INITIATED 16:18:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       523 TO ITERATE

100.0% PROCESSED      523 ITERATIONS                              157 ANSWERS
SEARCH TIME: 00.00.01

L3          157 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                168.70     168.91

FILE 'CAPLUS' ENTERED AT 16:18:47 ON 22 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Sep 2006  VOL 145 ISS 14
FILE LAST UPDATED: 21 Sep 2006  (20060921/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            3 L3

=> d ibib abs hitstr tot

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1021739  CAPLUS  Full-text
DOCUMENT NUMBER:          143:326208
TITLE:                    Preparation of diamino-mono-ol dipeptide isostere core
                          based resistance-repellent retroviral protease
                          inhibitors
INVENTOR(S):              Eissenstat, Michael; Guerassina, Tatiana
PATENT ASSIGNEE(S):       Sequoia Pharmaceuticals, Inc., USA
SOURCE:                   PCT Int. Appl., 78 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     --------------       ----   --------    --------------------    --------
```

Not art
late





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

Current application

ACCESSION NUMBER: 2004:162694 CAPLUS Full-text
DOCUMENT NUMBER: 140:210820
TITLE: Broad spectrum substituted oxindole sulfonamide HIV protease inhibitors
INVENTOR(S): Tahri, Abdellah; Wigerinck, Piet Tom Bert Paul
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016619	A1	20040226	WO 2003-EP50379	20030814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493940	AA	20040226	CA 2003-2493940	20030814
AU 2003262574	A1	20040303	AU 2003-262574	20030814
BR 2003005771	A	20041005	BR 2003-5771	20030814
EP 1546153	A1	20050629	EP 2003-787818	20030814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1688586	A	20051026	CN 2003-824095		20030814
JP 2005537305	T2	20051208	JP 2004-528524		20030814
US 2006058368	A1	20060316	US 2005-524451		20050210
NO 2005001291	A	20050518	NO 2005-1291		20050314
PRIORITY APPLN. INFO.:			EP 2002-78384	A	20020814
			WO 2003-EP50379	W	20030814

OTHER SOURCE(S): MARPAT 140:210820

GI



I



II

AB The present invention concerns the compds. having the formula (I) N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters, and metabolites thereof [wherein R1, R8 = H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, aryl, Het1, Het1-C1-6 alkyl, etc.; or R1 = (un)substituted H2N-CH2CH; t is 0, 1 or 2; R2 = H, C1-6 alkyl; L = CO, O-CO, NR8CO, O-C1-6 alkanediyl-CO, NR8-C1-6alkanediyl-CO, SO2, O-SO2, NR8-SO2; R3 = (un)substituted C1-6 alkyl, aryl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, aryl-C1-4alkyl; R4 = H, C1-4 alkyl-O-CO, carboxyl, CONH2, mono- or di(C1-4alkyl)carbamoyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl; R6 = H, (un)substituted C1-6 alkyl; Het1 is a 5 to 10 ring membered mono- or bicyclic heterocycle contg. .gtoreq.1 heteroatoms selected from N, O, and S]. It further relates to their use as broad spectrum HIV protease inhibitors, pharmaceutical compns., and a method for treating or combating infection or disease assocd. with multi-drug resistant retrovirus infection in a mammal. It also may concern combinations thereof with another anti-retroviral agent, and to their use in assays as ref. compds. or as reagents. These compds. I exhibited potent anti-HIV activity against a wild type lab. HIV strain (HIV-1 strain L-AI), e.g. sec50 of 8.5 for the compd. (II), and also were effective in inhibiting a broad range of mutant strains which show various degrees of phenotypic cross-resistance to the currently com. available drugs such as for instance saquinavir, ritonavir, nelfinavir, indinavir and amprenavir.

IT 664344-03-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(substituted oxindolesulfonamide derivs. for use as broad spectrum HIV protease inhibitors)

RN 664344-03-0 CAPLUS

—CO_2H

RN 664344-45-0 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2,3-dihydro-3-(2-methylpropylidene)-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 664344-46-1 CAPLUS
CN Carbamic acid, [3-[[[2,3-dihydro-3-(2-methylpropylidene)-2-oxo-1H-indol-5-yl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

late one, PRD 8/14/02

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:665557 CAPLUS Full-text
DOCUMENT NUMBER: 139:358012
TITLE: Potent small molecule inhibitors of spleen tyrosine kinase (Syk)
AUTHOR(S): Lai, Justine Y. Q.; Cox, Paul J.; Patel, Rajesh; Sadiq, Shazia; Aldous, David J.; Thurairatnam, Sukanthini; Smith, Keith; Wheeler, Darren; Jagpal, Savita; Parveen, Sofia; Fenton, Gary; Harrison, Trevor K. P.; McCarthy, Clive; Bamborough, Paul
CORPORATE SOURCE: Aventis Pharmaceuticals, Brigdewater, NJ, 08807, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),

13(18), 3111-3114
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:358012
GI



I

AB A series of oxindoles demonstrating inhibition of the phosphorylation of biotinylated substrates of Syk and IgE/Fc.epsilon.ERI triggered basophil cell degranulation has been identified. A study of the SAR around sulfonamide I (R = SO2NH2) (IC50=5 nM, EC50=1400 nM) is discussed. The modest cellular activity representative of the sulfonamide series was overcome when the Polar Surface Area was lowered to <110 A2, leading to the identification of amide II (R = CONHMe) (IC50=145 nM, EC50=100 nM).

IT 622388-05-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxindoles as inhibitors of spleen tyrosine kinase)

RN 622388-05-0 CAPLUS

CN Propanamide, 3-[[[2,3-dihydro-3-[(5-methoxy-1-methyl-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---